Associations between serum lipid levels and cognitive impairment in hypertensive patients: a case-control study

Shunxin Lv1, Huachen Jiao2, Xia Zhong3

  • 1First Clinical Medical School, Shandong University of Traditional Chinese Medicine, No. 42, Wenhua West Road, Lixia District, Jinan, Shandong, The People's Republic of China.

BMC Neurology
|July 2, 2025
PubMed

Insights

Lower serum low-density lipoprotein cholesterol (LDL-C) levels are linked to cognitive impairment (CI) in hypertensive patients. This suggests LDL-C may serve as a biomarker for cognitive screening in this population.

Area of Science:

  • Neurology
  • Cardiology
  • Biochemistry

Background:

  • Previous research indicates a link between low serum lipid levels and cognitive decline.
  • The specific relationship between serum lipids and cognitive impairment in hypertensive individuals remains underexplored.

Purpose of the Study:

  • To investigate the association between serum lipid profiles and cognitive impairment (CI) in patients with hypertension.

Main Methods:

  • A case-control study involving 1840 hypertensive patients (460 with CI, 1380 without).
  • Cognitive function assessed using the Mini-mental State Examination (MMSE); sleep quality via Pittsburgh Sleep Quality Index (PSQI).
  • Multifactorial logistic regression and Spearman's correlation analyzed the relationship between lipid levels, cognitive function, and sleep quality.

Main Results:

  • Lower serum low-density lipoprotein cholesterol (LDL-C) levels were significantly associated with reduced risk of CI in hypertensive patients (OR=0.823).
  • This association persisted in patients with at least a junior high school education (OR=0.727).
  • Serum LDL-C levels positively correlated with MMSE scores across various cognitive domains and negatively correlated with PSQI scores; serum total cholesterol (TC) and triglycerides (TG) showed no significant correlation with CI.

Conclusions:

  • Lower serum LDL-C levels are associated with cognitive impairment in hypertensive patients.
  • LDL-C may be a valuable biomarker for cognitive screening in this demographic.
  • Individualized management of serum lipid levels is recommended for hypertensive patients.
Abstract

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
58
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
298
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
67
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
51